10.1371/journal.pone.0096411 37
New obesity drugs are coming, including the 'triple agonist' Retatrutide (expected for approval in 2027), which activates 3 receptors: GLP1, GIP, and glucagon In a trial, Retatrutide caused loss of ~25% of bodyweight (in patients with obesity) in less than a year: New obesity drugs are coming, including the 'triple agonist' Retatrutide (expected for approval in 2027), which activates 3 receptors: GLP1, GIP, and glucagon In a trial, Retatrutide caused loss of ~25% of bodyweight (in patients with obesity) in less than a year: 25% in a year might be a little fast
Pain management specialists use injections as tools for both diagnosis and treatment when more conservative treatments, such as medication and physical therapy, do not provide relief from back and neck pain
If you want to know how to make your weight management better with Mounjaro, it is good to look at the right dose
(2025, October 22)